指南与共识免疫规划传染病防控与疫情报告卫生政策与健康促进

国际登革热倡议专家组关于CYD-TDV疫苗在拉丁美洲实施的更新建议

Updated recommendations of the International Dengue Initiative expert group for CYD-TDV vaccine implementation in Latin America.
指南 / 共识 · Vaccine · 2019-09-09

本文介绍国际登革热倡议(IDI)第六次会议(2018年6月)的主要结论,基于疫苗新标签、WHO-SAGE更新建议、新科学证据及实施国经验,讨论拉丁美洲CYD-TDV疫苗的两种接种策略(血清阳性率策略或接种前筛查策略)的利弊与实施考量。

要点

  • WHO推荐CYD-TDV用于9岁及以上、高传播率人群(基于血清阳性率或接种前筛查),或中低传播率地区有确诊既往感染者。
  • 高传播地区一般偏好血清阳性率策略;成本效果有利时,接种前筛查是便捷替代方案。
  • 疫苗引入应作为公共卫生策略的一部分,涉及多部门参与并确保稳健的沟通计划。

核心结论

  • 高传播地区一般偏好血清阳性率策略,成本效果有利时接种前筛查为便捷替代。
  • 成本效果评估可辅助公共卫生当局决策是否引入疫苗。
  • 疫苗引入应作为包含多部门参与和稳健沟通计划的公共卫生策略的一部分。

研究设计与样本

  • 国际登革热倡议(IDI)第六次会议(2018年6月)的专家讨论与结论总结。

主要发现

  • 会议基于疫苗新标签、WHO-SAGE更新建议、疫苗性能新科学证据及实施国经验进行讨论。
  • 讨论了拉丁美洲实施WHO-SAGE推荐的两种疫苗接种策略的利弊。
  • 强调需改善区域流行病学和监测数据质量以帮助确定两种策略的便利性。

关键数值与推荐

  • WHO推荐CYD-TDV用于9岁及以上、高传播率人群(基于血清阳性率标准或接种前筛查策略)。
  • WHO推荐CYD-TDV用于中低传播率地区有确诊既往感染者。

临床怎么用

  • 公共卫生当局可依据成本效果评估决定是否引入疫苗。
  • 实施时应选择血清阳性率策略或接种前筛查策略,并确保多部门参与和沟通。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Dengue disease represents a large and growing global threat to public health, causing a significant burden to health systems of endemic countries. For countries considering vaccination as part of their Integrated Management Strategy for Prevention and Control of Dengue, the World Health Organization currently recommends the first licensed dengue vaccine, CYD-TDV for: individuals aged 9 years or above from populations with high transmission rates, based on either seroprevalence criteria or pre-vaccination screening strategies, and for persons with confirmed prior exposure to infection in moderate to lower transmission settings. This paper describes the main conclusions of the Sixth Meeting of the International Dengue Initiative (IDI) held in June 2018, following release of a new product label by the manufacturer, updated WHO-SAGE recommendations, additional scientific evidence on vaccine performance, and reports of experiences by implementing countries. Considerations were made regarding the need for improving the quality of epidemiological and surveillance data in the region to help define the convenience of either of the two vaccination strategies recommended by WHO-SAGE. Extensive discussion was dedicated to the pros and cons of implementing either of such strategies in Latin America. Although, in general, a seroprevalence-based approach was preferred in high transmission settings, when cost-effectivity is favorable pre-vaccination screening is a convenient alternative. Cost-effectiveness evaluations can assist with the decisions by public health authorities of whether to introduce a vaccine. Where implemented, vaccine introduction should be part of a public health strategy that includes the participation of multiple sectors of society, incorporating input from scientific societies, ministries of heath, and civil society, while ensuring a robust communication program.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Torres JR, Falleiros-Arlant LH, Gessner BD, et al. Updated recommendations of the International Dengue Initiative expert group for CYD-TDV vaccine implementation in Latin America. Vaccine. 2019. PMID: 31515144. doi:10.1016/j.vaccine.2019.09.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。